Fig. 7
Antitumor efficacy of CAR-NK cells co-expressing IL-21 in vivo. A Schema of in vivo studies. Briefly, NSG mice received 5 × 105 Raji cells IV followed by 5 × 106 NK cells IV injection on day 4, containing 85% to 95% CAR positive NK cells. B Tumor burden was monitored using IVIS, and representative data of the bioluminescence mice are show. C The average radiance is shown for the untreated group, as well as CAR, CAR-15 and CAR-21 NK cell treatment groups of mice (n = 3). D Body weight of mice was monitored every 2 to 5 days (n = 3); asterisks depict statistical significance for the comparison. Red asterisks: CAR-21 vs CAR-15 NK; blue asterisks: CAR-15 vs CAR NK; one-way ANOVA with Bonferroni correction. E Kaplan-Meier survival curve of mice receiving tumor only and CAR-NK cells treatment (n = 5); log rank test. Data was collected from another independent experiments. F FACS showing the percentage of CAR+ NK cells (CD56+ mCherry+) present in organs from mice treated with CAR, CAR-15, and CAR-21 NK cells at day 33.